MedPath

Optimizing propofol dosing for (preterm) newborn infants that need endotracheal intubatio

Completed
Conditions
sedatie bij verrichting
sedation
Registration Number
NL-OMON45172
Lead Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Brief Summary

Trial is onging in other countries

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
91
Inclusion Criteria

All neonates admitted to the participating intensive care units:
Less than 28 days postnatal age
Who need endotracheal intubation

Exclusion Criteria

Patients with:
Major congenital anomalies or neurological disorders,
Neonates with an abnormal upper airway,
Those receiving continuous sedatives or opioids, and
Those whose mothers received sedatives or opioids before or during delivery will be excluded during the first 2 days of life.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Main study parameters/endpoints: Primary outcome is the appropriate dose of<br /><br>propofol in 8 different age groups. Optimized propofol doses need to be related<br /><br>with adequate sedation, good quality of intubation conditions and no short term<br /><br>side effects. </p><br>
Secondary Outcome Measures
NameTimeMethod
<p>Secondary endpoints include further evaluation of cerebral perfusion, stress<br /><br>levels and short and long term outcome of the included patients. The<br /><br>incorporation of PK data and genotype of patients is used to make a prediction<br /><br>model for future patients that includes various important cofactors, related to<br /><br>effects and side effects of propofol. Physiological and behavioural responses<br /><br>of the newborns are further explored to find the most reliable and validate<br /><br>neonatal sedation score for intubations. </p><br>
© Copyright 2025. All Rights Reserved by MedPath